Time on therapy and concomitant medication use of...

Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study

Abstract

About half of the patients who initiate therapy with mepolizumab discontinue treatment within the first or second year. Concomitant use of short-acting β₂-agonists and oral corticosteroids drops during mepolizumab use. https://bit.ly/3aRISqS.

Authors

Lee JK; Gendron A; Knutson M; Sriskandarajah N; Mbuagbaw L; Noorduyn SG

Journal

ERJ Open Research, Vol. 7, No. 1, pp. 00778–02020

Publisher

European Respiratory Society (ERS)

Publication Date

January 1, 2021

DOI

10.1183/23120541.00778-2020

ISSN

2312-0541

Associated Experts

Lawrence Mbuagbaw

Professor, Faculty of Health Sciences

Visit profile

Labels

Fields of Research (FoR)

32 Biomedical and Clinical Sciences 3202 Clinical Sciences 3201 Cardiovascular medicine and haematology 3211 Oncology and carcinogenesis

View published work (Non-McMaster Users)

View published work (McMaster Users)

Contact the Experts team

Get technical help

Provide website feedback